Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma

European Journal of Haematology

Volumn 71, Issue 3, 2003, Pages 179-183

  Kaufmann, Hannes ^a,b   Krömer, Elisabeth ^c,e   Nösslinger, Thomas ^d   Weltermann, Ansgar ^a,b   Ackermann, Jutta ^a,b   Reisner, Regina ^d   Bernhart, Marianne ^d   Drach, Johannes ^a,b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d Wilhelminenhospital   (Austria)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Chromosome 13; Cytogenetics; FISH; Multiple myeloma; Prognosis

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME ABERRATION; CYTOGENETICS; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; INTERPHASE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; METAPHASE; MONOSOMY; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELLS, CULTURED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 13; CYTOGENETIC ANALYSIS; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; KARYOTYPING; MALE; METAPHASE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS;

EID: 0042334481     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00111.x     Document Type: Article

References (23)

1. ZANDECKI M, LAI JL, FACON T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996;94:217-227.
2. TRICOT G, BARLOGIE B, JAGANNATH S, BRACY D, MATTOX S, VESOLE DH, NAUCKE S, SAWYER J-R. Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotypic abnormalities. Blood 1995;86:4250-4256.
3. TRICOT G, SAWYER JR, JAGANNATH S, DESIKAN KR, SIEGEL D, NAUCKE S, MATTOX S, BRACY D, MUNSHI N, BARLOGIE B. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997;15:2659-2666.
4. SEONG C, DELASALLE K, HAYES K, WEBER D, DIMOPOULOS M, SWANTKOWSKI J, HUH Y, GLASSMAN A, CHAMPLIN R, ALEXANIAN R. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998;101:189-194.
5. DESIKAN R, BARLOGIE B, SAWYER J, et al. Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;96:4008-4010.
6. PEREZ-SIMON JA, GARCIA-SANZ R, TABERNERO MD, ALMEIDA J, GONZALEZ M, FERNANDEZ-CALVO J, MORO MJ, HERNANDEZ JM, SAN-MIGUEL JF, ORFAO A. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998;91:3366-3371.
7. ZOJER N, KONIGSBERG R, ACKERMANN J, et al. In multiple myeloma, deletion of 13q14 remains an independent adverse prognostic parameter despite its frequent detection by interphase FISH. Blood 2000;95:1925-1930.
8. FACON T, AVET-LOISEAU H, GUILLERM G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-1571.
9. WOREL N, GREINIX H, ACKERMANN J, KAUFMANN H, URBAUER E, HOCKER P, GISSLINGER H, LECHNER K, KALHS P, DRACH J. Deletion of chromosome 13q14 detected by FISH has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol 2001;80:345-348.
10. FONSECA R, HARRINGTON D, OKEN MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res 2002;62:715-720.
11. SHAUGHNESSY J, BARLOGIE B, MCCOY J, SAWYER J, FASSAS A, ZANGARI M, MUWALLA F, CROWLEY J, TRICOT G. Early relapse after total therapy II for multiple myeloma (MM) is significantly associated with cytogenetic abnormalities of chromosome 13 (CA13) but not interphase FISH-del 13 or plasma cell labeling index PCLI. Blood 2001;98:734a (Abstract 3060).
12. SCHWEIZER D. Simultaneous fluorescent staining of R bands and specific heterochromatic regions (DA-DAPI bands) in human chromosomes. Cytogenet Cell Genet 1980;27:190.
13. SCHWEIZER D. Counterstain-enhanced chromosome banding. Hum Genet 1981;57:1.
14. ISCN. 1995. In MITELMAN F, ed. An international system for human cytogenetic nomenclature. Basel: S.Karger.
15. ACKERMANN J, MEIDLINGER P, ZOJER N, GISSLINGER H, LUDWIG H, HUBER H, DRACH J. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br J Haematol 1998;103:1161-1163.
16. KONIGSBERG R, ACKERMANN J, KAUFMANN H, et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 2000;14:1975-1979.
17. SAWYER JR, WALDRON JA, JAGANNATH S, BARLOGIE B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer-Genet-Cytogenet 1995;82:41-49.
18. CALASANZ MJ, CIGUDOSA JC, ODERO MD, FERREIRA C, ARDANAZ MT, FRAILE A, CARRASCO JL, SOLE F, CUESTA B, GULLON A. Cytogenetc analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes and Cancer 1997;18:84-93.
19. LAI JL, ZANDECKI M, MARY JY, BERNARDI F, IZYDORCZYK V, FLACTIF M, MOREL P, JOUET JP, BAUTERS F, FACON T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995;85:2490-2497.
20. SMADJA NV, BASTARD C, BRIGAUDEAU C, LEROUX D, FRUCHART C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-2238.
21. FONSECA R, OKEN MM, HARRINGTON D, BAILEY RJ, VAN-WIER SA, HENDERSON KJ, KAY NE, VAN-NESS B, GREIPP PR, DEWALD GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia 2001;15:981-986.
22. RAJKUMAR SV, FONSECA R, DEWALD GW, THERNEAU TM, LACY MQ, KYLE RA, GREIP PR, GERTZ MA. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999;113:73-77.
23. FASSAS AB, SPENCER T, SAWYER J, ZANGARI M, LEE CK, ANAISSIE E, MUWALLA F, MORRIS C, BARLOGIE B, TRICOT G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118:1041-1047.